GENE ONLINE|News &
Opinion
Blog

2025-11-28|

Advances in Mass Spectrometry Enhance Protein Analysis from Formalin-Fixed Paraffin-Embedded Tissues

by GOAI
Share To

Recent developments in mass spectrometry-based proteomics have highlighted its growing importance in analyzing formalin-fixed, paraffin-embedded (FFPE) tissues. FFPE samples, widely used in pathology for their ability to preserve cellular morphology over extended periods, have historically posed challenges for biochemical analysis due to alterations caused during the fixation and embedding processes. These advancements aim to address these limitations, making FFPE tissue proteomics a critical tool in clinical research.

The fixation process, which involves formalin treatment followed by paraffin embedding, has long been a standard method for preserving tissue samples. However, this process introduces chemical modifications that complicate protein extraction and analysis. Recent innovations in mass spectrometry techniques are overcoming these barriers by improving the recovery and identification of proteins from FFPE tissues. Researchers continue to explore ways to refine these methods further while addressing remaining challenges associated with sample preparation and data interpretation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top